TrialInvestigational new drugs2014

Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.

Johanna C Bendell et al.PubMed ↗Publisher ↗

No numbers read from the abstract.